Abstracts tagged "Psoriatic arthritis"

Abstract Number: 1781 • ACR Convergence 2021
A Direct-to-Patient PsA Screening Survey for Earlier Identification of At-Risk Psoriasis Patients and Reduction of Physician Burden
Megan Meier¹, Jessica Walsh² and Shaobo Pei³, ¹University of Utah, Salt Lake City, UT, ²Salt Lake City Veteran Affairs Medical Center (VAMC)/University of Utah Hospital, Salt Lake City, UT, ³Salt Lake City Veteran Affairs and University of Utah Medical Centers, Salt Lake City, UT
Background/Purpose: Diagnostic delays are common with psoriatic arthritis (PsA) and contribute to unnecessary impairments in quality of life and function. Screening surveys for identifying at-risk…
Abstract Number: 1798 • ACR Convergence 2021
The Transition to Psoriatic Arthritis: What Factors Predict a Shorter Transition from Psoriasis to Psoriatic Arthritis?
Shashank Cheemalavagu¹, Yuxuan Jin² and Elaine Husni², ¹Cleveland Clinic Foundation, Cleveland, OH, ²Cleveland Clinic, Cleveland, OH
Background/Purpose: Psoriatic arthritis (PsA) occurs in up to 30% of patients with psoriasis (PsO), and usually follows the development of PsO by an average of…
Abstract Number: 1816 • ACR Convergence 2021
Treatment of Non-biologic-DMARD-IR PsA Patients with Upadacitinib or Adalimumab Results in the Modulation of Distinct Functional Pathways: Proteomics Analysis of a Phase 3 Study
Thierry Sornasse¹, Jaclyn Anderson², Koji Kato³, Apinya Lertratanakul⁴, Christopher Ritchlin⁵ and Iain McInnes⁶, ¹AbbVie Inc, Redwood City, CA, ²AbbVie Inc, Gurnee, IL, ³AbbVie Inc, Shinagawa- Ku, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵Division of Allergy, Immunology, and Rheumatology, School of Medicine and Dentistry, University of Rochester Medical Center, Rochester, NY, ⁶University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom
Background/Purpose: Treatment of non-biologic-DMARD-IR (DMARD-IR) PsA patients with upadacitinib (UPA) at 15 mg QD, an oral JAK1 selective inhibitor, resulted in improvement in musculoskeletal symptoms,…
Abstract Number: 1835 • ACR Convergence 2021
Secukinumab Effects on Cardiometabolic Risk and Systemic Inflammation in Patients with Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis: Results from Post Hoc Analyses of Pooled Data from 19 Phase 3/4 Clinical Studies
Joseph Merola¹, Iain McInnes², Atul Deodhar³, Erhard Quebe-Fehling⁴, Maher Aassi⁴, Michael Peine⁴ and Nehal Mehta⁵, ¹Department of Dermatology and Department of Medicine, Division of Rheumatology; Brigham and Women's Hospital, Harvard Medical School, Newton, MA, ²University of Glasgow, School of Medicine, Glasgow, Scotland, United Kingdom, ³Oregon Health & Science University, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland, ⁵NHLBI/National Institutes of Health, Bethesda, MD
Background/Purpose: Psoriasis (PsO), Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (AxSpA) are chronic immune-mediated inflammatory diseases (IMIDs) requiring long-term treatment. Systemic inflammation in these IMIDs is…
Abstract Number: 0056 • ACR Convergence 2021
Peripheral Blood Immune Cell Profiling in Psoriatic Arthritis: Comparison of Patients with Healthy Controls
Lihi Eder¹, Darshini Ganatra² and Vinod Chandran³, ¹University of Toronto, Toronto, ON, Canada, ²University Health Network, Toronto, ON, Canada, ³Schroeder Arthritis Institute, Krembil Research Institute, Toronto Western Hospital, Toronto, ON, Canada
Background/Purpose: Heterogeneity in immune cell populations among patients with psoriatic arthritis (PsA) may determine disease expression and treatment response. The objective of this study was…
Abstract Number: 0239 • ACR Convergence 2021
Work Disability Associated with Fatigue in Patients with Psoriatic Arthritis – a Retrospective Study Using Claims Data, 2009-2019
Elaine Husni¹, Steven Peterson², Natalie Dennis³, Feifei Yang⁴, Iris Lin⁴, Yiting Wang⁵, Soumya Chakravarty⁶, Claire Fischer³, May Shawi⁷, Arthur Quenéchdu³ and Joseph Merola⁸, ¹Cleveland Clinic, Cleveland, OH, ²Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ, ³Amaris, Health Economics and Market Access, Paris, France, ⁴Janssen Immunology Global Commercial Strategy Organization, Horsham, PA, ⁵Janssen R&D, LLC, Titusville, NJ, ⁶Janssen Scientific Affairs, LLC and Drexel University College of Medicine, Horsham, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Brigham and Women’s Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Fatigue is a complex symptom affecting physiological, psychological, and social factors and is commonly seen in psoriatic arthritis (PsA). Fatigue has been shown to…
Abstract Number: 0750 • ACR Convergence 2021
Effect of Deucravacitinib on the Psoriatic Arthritis Impact of Disease Questionnaires 12 and 9: Analysis of a Phase 2 Study of Active Psoriatic Arthritis
Laure Gossec¹, Laura Coates², Alexis Ogdie-Beatty³, Philip Mease⁴, Tom Lehman⁵, Miroslawa Nowak⁵, Lan Wei⁵, June Ye⁵, Jiyoon Choi⁵, Joe Zhuo⁵ and Brandon Becker⁵, ¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³University of Pennsylvania, Philadelphia, PA, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁵Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by cytokines, such as IL-23, IL-12, and IFNα/β, involved in the pathogenesis of…
Abstract Number: 1165 • ACR Convergence 2021
“What Matters”: Patient and Clinician Perspectives in Psoriatic Arthritis Care
Philip Mease¹, Dan Furst², Evan Siegel³, Vibeke Strand⁴, Melissa Mcilraith⁵, Elaine Husni⁶ and M. Cameron Hay⁷, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²University of California Los Angeles, Los Angeles, CA, ³Arthritis and Rheumatism Associates, Potomac, MD, ⁴Stanford University School of Medicine, Portola Valley, CA, ⁵M.Mc. Consulting, Dallas, TX, ⁶Cleveland Clinic, Cleveland, OH, ⁷Miami University (Ohio), Oxford, OH
Background/Purpose: Recent psoriatic arthritis (PsA) treatment recommendations (1), highlight the importance of shared decision making; this ideally requires the clinician understands “what matters” to each…
Abstract Number: 1331 • ACR Convergence 2021
Guselkumab (TREMFYA®) Improves Anemia in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Randomized Controlled Clinical Trials
Arthur Kavanaugh¹, Yan Liu², Proton Rahman³, Philip Mease⁴, Laure Gossec⁵, Xie Xu², Elizabeth Hsia², May Shawi⁶, Chenglong Han², Marlies Neuhold⁷ and Atul Deodhar⁸, ¹University of California San Diego, La Jolla, CA, ²Janssen Research & Development, LLC, Spring House, PA, ³Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁴Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁵Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ⁶Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁷Janssen-Cilag, Zug, Switzerland, ⁸Oregon Health & Science University, Portland, OR
Background/Purpose: Anemia related to systemic inflammation can be an important feature of psoriatic arthritis (PsA). Hemoglobin (Hgb) levels have been shown to be inversely related…
Abstract Number: 1348 • ACR Convergence 2021
Predictors for Achievement of Low Disease Activity at Week 56 in Patients with Psoriatic Arthritis Who Received Upadacitinib 15 Mg Once Daily: Pooled Analysis of Two Phase 3 Studies
Daniel Aletaha¹, Philip Mease², Ralph Lippe³, Frank Behrens⁴, Derek Haaland⁵, Penélope Palominos⁶, Apinya Lertratanakul⁷, Michael Lane⁸, Kevin Douglas⁷, Peter Nash⁹ and Arthur Kavanaugh¹⁰, ¹Medical University Vienna, Vienna, Austria, ²Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ³AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁴Rheumatology & Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Fraunhofer Cluster Immune-Mediated Diseases (CIMD), Frankfurt/Main, Germany, ⁵McMaster University, Hamilton, Ontario and The Waterside Clinic, Oro Medonte, ON, Canada, ⁶Division of Rheumatology, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil, ⁷AbbVie Inc., North Chicago, IL, ⁸AbbVie Inc., North Chicago, ⁹Griffith University, Brisbane, Australia, ¹⁰Division of Rheumatology, Allergy and Immunology, Department of Medicine, University of California San Diego, La Jolla, CA
Background/Purpose: Upadacitinib (UPA) 15 mg once daily (QD) has demonstrated efficacy and safety in patients with psoriatic arthritis (PsA) for up to 56 weeks in…
Abstract Number: 1424 • ACR Convergence 2021
Secukinumab Treatment in Children and Adolescents with Enthesitis-related Arthritis and Juvenile Psoriatic Arthritis: Efficacy and Safety Results from a Phase 3 Study
Hermine Brunner¹, Ivan Foeldvari², Ekaterina Alexeeva³, Nuray Ayaz⁴, Inmaculada Calvo Penads⁵, Ozgur Kasapcopur⁶, Vyacheslav Chasnyk⁷, Markus Hufnagel⁸, Zbigniew Zuber⁹, Grant Schulert¹, Seza Ozen¹⁰, Artem Popov¹¹, Athimalaipet Ramanan¹², Christiaan Scott¹³, Betul Sozeri¹⁴, Elena Zholobova¹⁵, Xuan Zhu¹⁶, Sarah Whelan¹⁷, Luminita Pricop¹⁸, Angelo Ravelli¹⁹, Alberto Martini²⁰, Daniel Lovell²¹ and Nicolino Ruperto²², ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Hamburger Zentrum fuer Kinder- und Jugendrheumatologie, Hamburg, Germany, ³Scientific Center of Children Health of RAMS, Moscow, Russia, ⁴Istanbul University, İstanbul, Turkey, ⁵Hospital Universitario y Politécnico La Fe, Valencia, Spain, ⁶Istanbul University-Cerrahpasa, İstanbul, Turkey, ⁷Saint-Petersburg State Pediatric Medical Academy, Saint Petersburg, Russia, ⁸Division of Pediatric Infectious Diseases and Rheumatology, Department of Pediatrics and Adolescent Medicine, University Hospital Medical Center Freiburg, Medical Faculty, University of Freiburg, Freiburg, Germany, ⁹Paediatric Rheumatology International Trials Organisation (PRINTO), Lodz, Poland, ¹⁰Hacettepe University Medical Faculty, Ankara, Turkey, ¹¹Ural State Medical University, Yekaterinburg, Russia, ¹²University of Bristol, Bristol, United Kingdom, ¹³Paediatric Rheumatology, University of Cape Town, Cape Town, South Africa, ¹⁴University of Health Sciences, Umraniye Tranining and Research Hospital Division of Pediatric Rheumatology, Istanbul, Turkey, ¹⁵First Moscow State Medical University n.a. I.M.Sechenov, Moscow, Russia, ¹⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ, ¹⁷Novartis, Dublin, Ireland, ¹⁸Novartis Pharmaceutical Corporation, East Hanover, NJ, ¹⁹Istituto Giannina Gaslini, Genoa, Italy, ²⁰IRCCS Istituto G. Gaslini, Università di Genova Pediatria II, Genova, Italy, ²¹Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ²²IRCCS Istituto Giannina Gaslini; PRINTO, Clinica Pediatrica e Reumatologia, Genova, Italy
Background/Purpose: Enthesitis-related arthritis (ERA) and juvenile psoriatic arthritis (JPsA) are two conditions that represent pediatric correlates of axial spondyloarthritis (axSpA) and adult psoriatic arthritis (PsA),…
Abstract Number: 1782 • ACR Convergence 2021
Disease Activity in Psoriatic Arthritis Patients with Enthesitis Across Different Therapies
Robert Chao¹, George Reed², Joel Kremer³ and Arthur Kavanaugh⁴, ¹Inova Health System, Fairfax, VA, ²University of Massachusetts, Worcester, MA, ³Department of Medicine, Center for Rheumatology, Albany Medical College, Albany, FL, ⁴University of California San Diego, La Jolla, CA
Background/Purpose: Evidence on the treatment of enthesitis, a common feature of psoriatic arthritis (PsA), is limited. This post-hoc, cross-sectional study examined if prevalent treatment choices…
Abstract Number: 1799 • ACR Convergence 2021
Gender Based Differences in Clinical and Sonographic Assessment Among Patients with Psoriatic Arthritis
Victoria Furer¹, Jonathan Wollman², David levartovsky³, Valerie Aloush³, Sara Borok Lev-Ran⁴, Daphna Paran⁵, Ori Elkayam³ and Ari Polachek⁶, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Medical Center, Herzliya, Israel, ³Tel Aviv Medical Center, Tel Aviv, Israel, ⁴Sourasky Medical Center, Tel AViv, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Sourasky Medical Center, Petah-Tikva, Israel
Background/Purpose: Psoriatic arthritis (PsA) can affect differently women and men. Ultrasound (US) is an important tool in the evaluation of disease activity of PsA. To…
Abstract Number: 1817 • ACR Convergence 2021
Comparison of Composite Indices for Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib: A Post-Hoc Analysis from SELECT-PsA 1
Josef Smolen¹, Ennio Lubrano², Mitsumasa Kishimoto³, Andra R Bălănescu⁴, Vibeke Strand⁵, Tianming Gao⁶, Nancy Vranich⁶, Ralph Lippe⁷ and William Tillett⁸, ¹Medical University of Vienna, Vienna, Austria, ²Department of Medicine and Health Sciences Vincenzo Tiberio, University of Molise, Campobasso, Italy, ³Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan, ⁴“Carol Davila” University of Medicine and Pharmacy, Department of Internal Medicine and Rheumatology “Sf. Maria” Hospital, Bucharest, Romania, ⁵Stanford University School of Medicine, Portola Valley, CA, ⁶AbbVie Inc., North Chicago, IL, ⁷AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁸Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom
Background/Purpose: Achieving low disease activity (LDA) or remission is a main treatment target in PsA. Composite indices used to assess disease activity include Disease Activity…
Abstract Number: 1910 • ACR Convergence 2021
Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial
Laure Gossec¹, Nemanja Damjanov², Shigeyoshi Tsuji³, Apinya Lertratanakul⁴, Ralph Lippe⁵, Jayeshkumar Patel⁴, Patrick Zueger⁶ and Kurt de Vlam⁷, ¹Sorbonne Université; APHP, Rheumatology Department, Pitié-Salpêtrière Hospital, Paris, France, ²University of Belgrade School of Medicine, Institute of Rheumatology, Belgrade, Serbia, ³Department of Orthopaedics/Rheumatology, National Hospital Organization, Osaka Minami Medical Center, Osaka, Japan, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁶AbbVie Inc., Mettawa, IL, ⁷Department of Rheumatology, Universitaire Ziekenhuizen Leuven, Leuven, Belgium
Background/Purpose: The achievement of disease control has been shown to be associated with improved prognosis in PsA, though no single measure of low disease activity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].